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Background & objectives: Levels of tumour necrosis factor (TNF) are increased in patients with
HIV infection leading to increased apoptosis and reduced CD4 cell life. Pentoxiphylline is a TNF
inhibitor with properties that might make it useful for the treatment of HIV infection. These include
improved cell mediated immunity and inhibition of viral replication. We carried out this study to
determine the therapeutic utility of pentoxiphylline in improving constitutional manifestations,
preventing opportunistic infections and sustaining CD4 counts among asymptomatic HIV infected
individuals (i.e., those with no opportunistic infection).
Methods: Individuals with HIV infection who were over 18 yr of age and free of opportunistic
infections were recruited in the study and followed up 4 weekly. CD4 counts were measured using
a flowcytometer using anti-human CD4 intervals. Pentoxiphylline was prescribed in a dose of
400 mg thrice daily.
Results: Thirty three (18 males) patients with HIV infection were studied. During their follow up
(mean 12.5 ± 5.6 months) one patient each developed cryptococcal meningitis and fibrocavitary
tuberculosis. Weight increased from 51.3 ± 7.4 kg at baseline to 55.3 ± 7.4 kg (P<0.05). Malaise,
fatigue and appetite improved in all those with these complaints, except the two with opportunistic
infections. Mean CD4 counts were 184 ± 36.4/µl at baseline and increased to 210 ± 28.6/µl3 at four
weeks (P<0.05). The patients had stable CD4 counts over the follow up period since then, i.e.,
within 25 per cent of the previous levels.
Interpretation & conclusion: Pentoxiphylline therapy in HIV infected individuals, who were free of
opportunistic infections, improved their body weight, minimized opportunistic infections, increased
and sustained CD4 counts. Given the low cost of the drug it could be recommended for the use in
individuals who are at a high risk of developing opportunistic infections.
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As of end 2004, there were approximately 39.4
million individuals infected with HIV world-wide1.
The current cost of antiretroviral therapy is
prohibitive for the majority of patients in most
developing countries and there is an urgent need
for effective, safe and cheap antiretrovirals2. The
only treatment modalities available for therapy for
the masses are those for opportunistic infections
that this does not take adequate care of the
immunodeficient state induced by the virus itself.
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Tumour necrosis factor-a (TNFa) levels rise in
patients with HIV infection3-5. TNFa  has significant
role in apoptosis, one of the major mechanisms of cell
death in AIDS6. It markedly enhances the in vitro
spread of  HIV-1 by increasing viral RNA synthesis7.
It may also be involved in several complications
associated with clinical AIDS such as wasting,
haematological, renal and neurological disorders8. It
has been suggested that blockade of TNF production
and/or receptor sites would benefit individuals with
HIV infection9. Anti-TNF agents include
phosphodiesterase inhibitors that inhibit TNF
synthesis9. Pentoxiphylline, a phosphodiesterase
inhibitor, blocks the accumulation of TNFa mRNA10.
Pentoxiphylline has been used earlier in the
therapy of patients with HIV infection and some
studies have shown benefit with respect to some
immunological parameters. Heinkelein et al11 showed
that pentoxiphylline might inhibit cytotoxicity and
cytokine secretion among patients with HIV infection.
It has been shown to improve cell-mediated immunity
and reduce plasma viraemia in asymptomatic HIV
seropositive persons12. It has also been suggested to
inhibit acute HIV-1 replication in human T cells by a
mechanism not involving inhibition of TNF synthesis
or nuclear factor-kappa B activation13. In standard
doses of 400 mg thrice daily the cost of the drug is
less than Rs 10 per day in India. We studied the
therapeutic benefit of pentoxiphylline in the
prevention of opportunistic infections and
improvement in constitutional manifestations in HIV
infected Indian patients.
Material & Methods
This study was carried out among HIV positive
individuals attending the Medical Outpatients
Department at Postgraduate Institute of Medical
Education and Research, Chandigarh, between 1999 and
2002. All the patients who were willing and eligible
for the study were included. In order to avoid
confounding variables among various parameters,
individuals with active opportunistic infection were not
included in the study. The following were the inclusion
criteria: age >18 yr, no opportunistic infection or
neoplasm, CD4 counts between 50 and
500/ml and willingness to participate in the trial. The
following were the exclusion criteria: age <18 yr, CD4
count more than 500 or less than 50/ml, Karnofsky score
<70, therapy with antiretrovirals, pregnant or lactating
women, hemoglobin <9 g/dl, absolute granulocyte count
<1000/ml, platelet count <25,000/ml, uric acid >8 mg/
dl, derangement in hepatic or renal functions (urea and
creatinine) to more than two times normal, active and
untreated infection, pregnant or lactating women,
intolerance to pentoxiphylline and refusal to give
informed consent. At baseline, a complete physical
examination was performed, along with routine tests
for haemogram, liver functions, X-ray chest and CD4
count.  The drug was prescribed in a dose of 400 mg
thrice daily. Follow up was made every four weeks with
clinical assessment, including body weight, and CD4
counts. Efforts to procure the drug and an identical
placebo from manufacturers of the drug in India were
unsuccessful; hence, this was an open label study. No
patient received co-trimoxazole prophylaxis.
At each 5 ml visit blood samples were collected.
Serum was separated and stored at -200C for future
analysis. Informed consent was taken at the time of
recruitment in the trial. The study was carried out
after obtaining permission from the Institute’s Ethics
Committee.
CD4 counts were measured on a flowcytometer
(Becton-Dickinson, USA) anti-human CD4-FITC
(Sigma Immunochemicals, USA). The results were
analyzed by two-way analysis of variance (ANOVA).
Pearson’s correlation coefficient was calculated to
determine correlation; P<0.05 was considered
significant.
Results
Thirty three (18 males) patients with HIV
infection were studied (Table I). Mean follow up of
these patients was 12.5 ± 5.6 months (range 6-20
months). Two patients developed infections during
the course of follow up. One patient developed
cryptococcal meningitis within four weeks and
another developed fibrocavitary tuberculosis six
months after initiation. The former was diagnosed
on cerebrospinal fluid culture and the latter by
positive acid-fast bacilli in the sputum. The patient
who developed cryptococcal meningitis had CD4
count of 0/ml and was subsequently started on triple
drug antiretroviral therapy. Six months after start of
this therapy his CD4 count was 64/ml. The other
patient was treated with standard anti-tubercular
therapy and was maintaining well one year later.
Weight increased from 51.3 ± 7.4 kg at baseline to
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55.3 ± 7.4 kg (P<0.05), the last recorded weight.
There has been return to gainful employment in eight
cases. Malaise, fatigue and appetite have improved in
all those with these complaints, except the two with
opportunistic infections. Mean CD4 counts were 184
± 36.4/ml at baseline and increased to 210 ± 28.6/ml at
four weeks (P<0.05). They have since remained
stable over the follow up period since then, i.e.,
within 25 per cent of the previous levels. The drug
was well tolerated with minimal side effects. Four
patients felt mild abdominal discomfort but none of
the patients had reason to discontinue the therapy.
Discussion
In this study, the use of pentoxiphylline led to
amelioration of constitutional symptoms in most
patients. Weight gain was sustained in virtually all
the patients. This led to gainful employment in eight
cases. Weight loss is usually progressive among HIV
infected individuals14. This process was halted and in
most of them original weight was restored. These
improvements had a positive influence on the patients
and improved their quality of life. At a price of less
than a quarter dollar per day, this may be a useful form
of therapy for HIV infected individuals. There were
only two opportunistic infections in our patients
despite the fact that individuals with CD4 count less
than 500/ml are known to be at an increased risk of
development of opportunistic infections15. CD4 counts
showed an increase and have been sustained over the
period of follow up. This is significant, as these counts
are indicative of the likelihood of the development of
opportunistic infections in the near future16. CD4 count
of 500 was taken as the cut-off since at the time of
start of study that was the indication of initiation of
antiretroviral therapy. The cost of pentoxiphylline is
far less than the cheapest triple drug regimen
(Table II). In a poor country like India this is an
important consideration. A useful corollary to this is
to institute this form of therapy and sustain the CD4
count for as long as possible and, thereby, delay the
time at which antiretroviral therapy needs to be
initiated. This alone could reduce the long-term cost
of treatment and reduce mortality and morbidity by
reducing opportunistic infections.
Several studies have documented the mechanisms
of action of pentoxiphylline in patients with HIV
infection. TNF-a was suppressed at four weeks with
this therapy17. Since it is responsible for weight loss,
its suppression is the likely explanation for weight gain
in our patients. With four weeks of this therapy, level
of nitric oxide production decreased significantly, as
demonstrated by its surrogate markers, nitrite and
citrulline17. In another study, there was a decline in
beta-2 microglobulin (B2M) levels after four weeks
of use of pentoxiphylline18. This assumes significance
in view of the importance of both immune defects, as
shown by decreased CD4 counts, and immune
stimulation, as shown by elevated B2M, in predicting
disease course and prognosis19. Immune stimulation
occurs very early in the course of HIV infection, as
evidenced by the demonstration of HIV antibodies in
the serum of these patients20. There is additional
importance of demonstrating immune stimulation in
these patients as these can predict the future rate of
decrease in CD4 count for at least two to three years20.
Elevated B2M can have predictive value at normal,
intermediate or markedly reduced CD4 counts19. The
possible mechanism of its action beyond TNF
inhibition needs to be elucidated. However, markers
of apoptosis, namely, caspase 1 and caspase 8 were
decreased significantly following four weeks of
pentoxiphylline21.
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Table I. Clinical profile of patients with HIV infection
Number 33
Age (yr) (range) 32.5 ± 5.9 (21-45)
Sex ratio: m : f 18 : 15
Route of transmission heterosexual 30, blood
transfusion 2, IVDU* 1
Past AIDS defining illness 8
Chief complaints at Loss of weight 28, malaise or
presentation fatigue 20, loss of appetite 18,
fever 12, enlarged lymph nodes 7
Hb, g/dl (range) 9.2 ± 0.8 (8.9 - 11.6)
*IVDU, intravenous drug user
Values are mean ± SD
Table II. Relative monthly costs (US$) of antiretroviral
combinations and pentoxiphylline in India in July 2005
Regimen Cost (US$)
Protease inhibitor based >120
Efavirenz 60
Nevirapine based (e.g., triple 30
drug combinations)
Pentoxiphylline 12
Source: MIMS India 2005; 25 : 5
An obvious pitfall in this study was that neither
patient nor the physician has been blinded to the
therapy and there was no placebo control. Efforts to
procure the drug and an identical placebo from
manufacturers of the drug in India were unsuccessful.
There have been four other patients outside this
clinical trial who have been administered this drug
for sometime and on gaining weight have
discontinued it. With this they lost weight and
appetite that was gained earlier. On restarting
pentoxiphylline both these parameters improved in
four weeks time.
In conclusion, a study with a large sample size and
a longer follow up needs to be carried out with a placebo
control arm, to see if the use of highly active
antiretroviral therapy (HAART) can be delayed. An
ancillary benefit of this drug is increase in body weight.
This too can be a pointer for improvement as the natural
course of HIV infection is such that either weight
remains the same or declines over a period of time.
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